EntreMed announces initiation of phase 2 trial in triple-negative breast cancer

EntreMed announced the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study. The study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute. More information about the clinical trial can be found at www.ClinicalTrials.gov.